Last reviewed · How we verify

Generalized anxiety disorder — Treatment Landscape & Competitive Intelligence

Generalized anxiety disorder (disease) competitive landscape: 9 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

9 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Generalized anxiety disorder, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Cymbalta duloxetine Eli Lilly and Company Serotonin and norepinephrine reuptake inhibitor (SNRI) Serotonin and norepinephrine reuptake 2004-08-03
Lexapro escitalopram Generic (originally Lundbeck/Forest) Selective Serotonin Reuptake Inhibitor (SSRI) Serotonin (5-HT) reuptake transporter 2002-08-14
Celexa CITALOPRAM AbbVie Serotonin Reuptake Inhibitor Sodium-dependent serotonin transporter 1998-01-01
Effexor venlafaxine Generic (originally Wyeth/Pfizer) SNRI (Serotonin-norepinephrine reuptake inhibitor) 5-hydroxytryptamine receptor 6, 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2C 1993-12-28
Effexor Venlafaxine Hydrochloride Pfizer Serotonin-Norepinephrine Reuptake Inhibitor (SNRI) Serotonin and norepinephrine reuptake transporters 1993-01-01
Xanax alprazolam Generic (originally Upjohn/Pfizer) Benzodiazepine (triazolobenzodiazepine) Bromodomain-containing protein 4, Platelet-activating factor receptor, Cytochrome P450 3A4 1981-10-16
Effexor Effexor Wyeth is now a wholly owned subsidiary of Pfizer 5-hydroxytryptamine receptor 6, 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2C
Cital Cital Ain Shams University Solute carrier family 22 member 1, 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B
Xanax Xanax National Taiwan University Hospital Bromodomain-containing protein 4, Platelet-activating factor receptor, Cytochrome P450 3A4

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. · 1 drug in Generalized anxiety disorder
  2. AbbVie · 1 drug in Generalized anxiety disorder
  3. Ain Shams University · 1 drug in Generalized anxiety disorder
  4. Eli Lilly and Company · 1 drug in Generalized anxiety disorder
  5. Generic (originally Lundbeck/Forest) · 1 drug in Generalized anxiety disorder
  6. Generic (originally Upjohn/Pfizer) · 1 drug in Generalized anxiety disorder
  7. Generic (originally Wyeth/Pfizer) · 1 drug in Generalized anxiety disorder
  8. National Taiwan University Hospital · 1 drug in Generalized anxiety disorder
  9. Pfizer · 1 drug in Generalized anxiety disorder
  10. Wyeth is now a wholly owned subsidiary of Pfizer · 1 drug in Generalized anxiety disorder

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Generalized anxiety disorder:

Cite this brief

Drug Landscape (2026). Generalized anxiety disorder — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/generalized-anxiety-disorder. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing